2nd Global Summit on

Herbals & Natural Remedies

October 17-19, 2016

Kuala Lumpur, Malaysia

HERBAL CARDIOCEUTICALS: II

OMBS Intermedia

Shashi K. Agarwal, MD, FACN, ABIHM, FAAIM, FACC, NJ, USA

Introduction: Cardiovascular diseases are the number one cause of morbidity and mortality in the world. Traditional herbal concoctions and herb derived drugs are commonly used for these ailments. These three abstracts review popular herbal remedies, which have demonstrated beneficial cardiovascular effects and results have been validated by rigorous scientific studies.

Methods: PubMed interrogation revealed 65,034 entries under 'herbal medicines' and 2,963 under 'herbal and cardiovascular'. Relevant citations were reviewed. Other pertinent published scientific material was also consulted.

Results: Commiphora mukul (Guggulipid):



Z- and E-guggulsterones are the active ingredients and inhibit cholesterol synthesis in the liver via antagonism of the farsenoid X receptor and the bile-acid receptor. The extract has received regulatory approval for treating

hyperlipidemia in India since 1987, while in the United States, guggulipid is available as a nonprescription dietary supplement.

Digitalis purpurea (Common Foxglove):



Digitalis is used for symptomatic chronic heart failure for patients with reduced systolic function, preservation of systolic function, and combined with beta blockers, in rate control for atrial fibrillation with a rapid ventricular response. Digitalis works by inhibiting sodium-potassium ATPase in the myocardium, causing intracellular sodium concentration to increase.

Ginkgo Biloba (Maidenhair tree):



Its terpenes inhibit platelet-activating factor, decrease vascular resistance, and improve

circulatory flow, while the flavonoids reduce capillary permeability and fragility. Clinical studies support its use in treating cerebral insufficiency. It may also help peripheral vascular disease.

Conclusions: Several herbal medicines have convincingly established their therapeutic role as cardioceuticals. Evidence based scrutiny has repeatedly validated their efficacy and safety in clinical trials.

References:

- 1. Villegas JF, Barabe DN, Stein RA, et al. Adverse effects of herbal treatment of cardiovascular disease: what the physician must know. Heart Dis. 2001 May-Jun;3(3):169-75.
- 2. Yilmaz MB, Yontar OC, Turgut OO, et al. Herbals in cardiovascular practice: are physicians neglecting anything? Int J Cardiol. 2007 Oct 31;122(1):48-51.
- 3. Cohen PA, Ernst E. Safety of herbal supplements: a guide for cardiologists. Cardiovasc Ther. 2010 Aug;28(4):246-53.
- 4. Szapary PO, Wolfe ML, Bloedon LT et al. Guggulipid for the treatment of hypercholesterolemia, a randomized controlled trial. JAMA. 2003; 290:765-72.
- 5. Jelliffe RW. The role of digitalis pharmacokinetics in converting atrial fibrillation and flutter to regular sinus rhythm. Clin Pharmacokinet. 2014 May;53(5):397-407.
- 6. Nash KM, Shah ZA. Current Perspectives on the Beneficial Role of Ginkgo biloba in Neurological and Cerebrovascular Disorders. Integr Med Insights. 2015 Nov 9;10:1-9.